We have located links that may give you full text access.
GOALS FOR MEDICAL TREATMENT IN OBESITY AND PREDIABETES: IMPROVING OUTCOMES FOR BOTH.
Endocrine Practice 2018 October 6
OBJECTIVE: The purpose of this review is to expose the surprising prevalence of diabetes-related complications in people with persistent prediabetes, and hence, to expand the paradigm of diabetes prevention to include the prevention of complications related to both hyperglycemia and obesity.
METHODS: Published literature was reviewed.
RESULTS: Approximately 84 million Americans have prediabetes, 85% of whom are overweight or obese. Although the incidence of diabetes-related complications is lower in people with prediabetes vs. type 2 diabetes, the overall prevalence is virtually identical. Further, many people with prediabetes not only suffer from the complications of related to hyperglycemia, they also experience complications of obesity. Treating obesity as a disease has the potential to prevent complications of both hyperglycemia and obesity. Emerging data reveals the untapped potential for clinicians to enhance the effectiveness of anti-obesity medications through a mindful health care delivery style. This involves an understanding and ethical utilization of the placebo effect in conjunction with active medical therapy. This approach is not intended to mislead patients, but rather to activate neurocircuitry that synergizes with the central action of the approved anti-obesity medications to potentiate weight loss.
CONCLUSIONS: Mindful administration of anti-obesity medications has the potential for widespread health benefits in people with obesity and prediabetes.
ABBREVIATIONS: ADA = American Diabetes Association; AACE = American Association of Clinical Endocrinologists; DPP = Diabetes Prevention Program; DPPOS = Diabetes Prevention Program Outcomes Study; MVD = Microvascular disease; CVD = Cardiovascular disease; NDPP = National Diabetes Prevention Program; CDC = Centers for Disease Control; eGFR = Estimated glomerular filtration rate; TZD = Thiazolidinedione; SGLT2 Sodium-glucose-like cotransporter-2.
METHODS: Published literature was reviewed.
RESULTS: Approximately 84 million Americans have prediabetes, 85% of whom are overweight or obese. Although the incidence of diabetes-related complications is lower in people with prediabetes vs. type 2 diabetes, the overall prevalence is virtually identical. Further, many people with prediabetes not only suffer from the complications of related to hyperglycemia, they also experience complications of obesity. Treating obesity as a disease has the potential to prevent complications of both hyperglycemia and obesity. Emerging data reveals the untapped potential for clinicians to enhance the effectiveness of anti-obesity medications through a mindful health care delivery style. This involves an understanding and ethical utilization of the placebo effect in conjunction with active medical therapy. This approach is not intended to mislead patients, but rather to activate neurocircuitry that synergizes with the central action of the approved anti-obesity medications to potentiate weight loss.
CONCLUSIONS: Mindful administration of anti-obesity medications has the potential for widespread health benefits in people with obesity and prediabetes.
ABBREVIATIONS: ADA = American Diabetes Association; AACE = American Association of Clinical Endocrinologists; DPP = Diabetes Prevention Program; DPPOS = Diabetes Prevention Program Outcomes Study; MVD = Microvascular disease; CVD = Cardiovascular disease; NDPP = National Diabetes Prevention Program; CDC = Centers for Disease Control; eGFR = Estimated glomerular filtration rate; TZD = Thiazolidinedione; SGLT2 Sodium-glucose-like cotransporter-2.
Full text links
Related Resources
Trending Papers
Mineralocorticoid receptor antagonists and reno-protection: What's the evidence & where do they fit? A guide for non-specialists.Diabetes, Obesity & Metabolism 2024 May 8
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.Pharmacological Research : the Official Journal of the Italian Pharmacological Society 2024 May 12
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app